Imbed Biosciences recently announced the launch of SAM PainGuard with Lidocaine, which encompasses Surgaflex PainGuard for surgical wounds and Pelashield PainGuard for burn and trauma wound management.

“Nearly 90% of patients report moderate to severe pain following surgery,” CEO Terry Bromley said in a statement. “Managing this pain effectively from the start is critical—not only to reduce reliance on systemic pain medications, including opioids, but also to prevent long-term complications such as anxiety, PTSD and delayed healing, which can be a challenge especially in burn care.”

The products, now available in the United States, join Microlyte, Surgaflex and Pelashield in Imbed Biosciences’ lineup of wound care solutions.